NCT00290849

ImproveR International (BI-001-IM)

European Registry of Consecutive Patients Undergoing PCI Evaluating the Use of the Thrombin-specific Anticoagulant Bivalirudin With Focus on Patient Selection, Convenience and Safety Aspects.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 4,000 (planned)
• Sponsor: Nycomed · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The objectives of this registry are to assess the use of the thrombin-specific anticoagulant bivalirudin during percutaneous coronary intervention (PCI) in a real life setting. In particular, data will be collected to analyze experiences of bivalirudin use in respect to the following objectives; * examine the aspects of safety and effectiveness of bivalirudin * gain experience regarding the characteristics of patients in bivalirudin treatment * evaluate the handling of bivalirudin and its practicality

Conditions

• Thrombin-specific Anticoagulant Bivalirudin During Percutaneous Coronary Intervention (PCI)

Interventions

Type	Name	Description
DRUG	Bivalirudin

Timeline

• Start date: 2005-03-01
• Primary completion: 2006-06-01
• Completion: 2007-09-01
• First posted: 2006-02-13
• Last updated: 2012-05-07

Locations

1 site across 1 country: Denmark